Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Latanoprostene bunod · 2 trials · 3 indications
Change from baseline in intraocular pressure (IOP) following treatment with latanoprostene bunod 0.024% (instilled QD in the evening) with IOP assessed every 4 weeks from Week 4 to Week 52.
Ocular adverse events reported over one year of once daily dosing of latanoprostene bunod 0.024%. Below is the percentage of subjects with \>/=1 ocular AE Specifics of AEs are captured in the AE section.
Efficacy of latanoprostene bunod dosed QD in reducing IOP from baseline. IOP to be measured at multiple time points at visit 3.
| Arm | Type | Description |
|---|---|---|
| Latanoprostene Bunod | EXPERIMENTAL | Latanoprostene bunod 0.024% instilled into the eye once daily (QD) over a 1-year treatment period. |
| Name | Type | Description |
|---|---|---|
| Latanoprostene bunod | DRUG | - |
Inclusion Criteria: * Subjects must have a diagnosis of open angle glaucoma (OAG) (including normal-tension glaucoma \[NTG\],pigmentary or pseudoexfoliative glaucoma), or ocular hypertension (OHT) in one or both eyes. * Subjects must meet the following IOP requirements at Visit 3 (Eligibility, Day ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 5 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
Latanoprostene bunod is an investigational small molecule being developed for lowering intraocular pressure in patients with glaucoma and ocular hypertension. It is administered as an ophthalmic solution and is currently in Phase 3 clinical development for these conditions.
Latanoprostene bunod is being developed by Bausch + Lomb Corporation, which trades under the ticker symbol BLCO. The company is conducting clinical trials to evaluate the drug's safety and efficacy in treating elevated intraocular pressure associated with glaucoma.
Latanoprostene bunod is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 3 trial has been completed to assess its long-term safety in patients with open-angle glaucoma or ocular hypertension.
Latanoprostene bunod has been studied in clinical trials registered under NCT01895972 and NCT01895985. The Phase 3 trial NCT01895972 evaluated long-term safety in 130 Japanese subjects with glaucoma or ocular hypertension, while the Phase 1 trial NCT01895985 assessed efficacy in healthy male volunteers.
Latanoprostene bunod is a small molecule that works by targeting the prostaglandin pathway to lower intraocular pressure. It is designed to reduce pressure in the eye, which is a key factor in managing glaucoma and ocular hypertension.